Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia

Clinical Biochemistry

Volumn 42, Issue 7-8, 2009, Pages 666-671

  Duarte, Marta M M F ^a   Rocha, João B T ^a   Moresco, Rafael N ^a   Duarte, Thiago ^a   Da Cruz, Ivana B M ^a   Loro, Vânia L ^a   Schetinger, Maria R C ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Hypercholesterolemia; Inflammation; Ischemia modified albumin; Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISCHEMIA MODIFIED ALBUMIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84984590435     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.01.010     Document Type: Article

References (45)

1. Kannel W.B., Castelli W.P., and Gordon T. Cholesterol in the prediction of atherosclerotic disease. Ann. Intern. Med. 90 (1979) 85-91
2. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
3. Kotur-Stevuljevic J., Memon L., Stefanovic A., et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin. Biochem. 40 (2007) 181-187
4. Matsuura E., Kobayashi K., Tabuchi M., and Lopez L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog. Lipid Res. 45 (2006) 466-486
5. Witztum J.L., and Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc. Med. 11 (2001) 93-102
6. Yla-Herttuala S., Palinski W., Butler S., Picard S., Steinberg D., and Witztum J. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14 (1994) 32-40
7. Duarte M.M.M.F., Loro V.L., Rocha J.B.T., et al. Enzymes that hydrolyze adenine nucleotides of patients with hypercholesterolemia and inflammatory processes. FEBS J. 274 (2007) 2707-2714
8. Ridker P.M., Wilson P.W.F., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
9. Armstrong E.J., Morrow D.A., and Sabatine M.S. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 113 (2006) 152-155
10. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1389
11. Francisco G., Hernández C., and Simó R. Serum markers of vascular inflammation in dyslipemia. Clin. Chim. Acta 369 (2006) 1-16
12. Vassalle C., Pratali L., Boni C., Mercuri A., and Ndreu R. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin. Biochem. 41 (2008) 1162-1167
13. Cichota L.C., Moresco R.N., Duarte M.M.M.F., and Paz da Silva J.E. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J. Clin. Lab. Anal. 22 (2008) 1-5
14. Roy D., Quiles J., Gaze D.C., Collinson P., Kaski J.C., and Baxter G.F. Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 92 (2006) 113-114
15. Sinha M.K., Roy D., Gaze D.C., Collinson P.O., and Kaski J.C. Role of "ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg. Med. J. 21 (2004) 29-34
16. Collinson O.P., Gaze D.C., Bainbridge K., et al. Utility of admission cardiac troponin and "ischemia modified albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg. Med. J. 23 (2006) 256-261
17. Peacock F., Morris D.L., Anwaruddin S., et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am. Heart J. 152 (2006) 253-262
18. Keating L., Benger J.R., Beetham R., et al. The PRIMA Study: presentation ischaemia-modified albumin in the emergency department. Emerg. Med. J. 23 (2006) 764-768
19. Skilton M.R., Moulin P., Sérusclat A., Nony P., and Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis 190 (2007) 416-422
20. Bachorik P.S., and Albers J.J. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 129 (1986) 78-100
21. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
22. Holvoet P., Stassen J.M., Van Cleemput J., Collen D., and Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 100-107
23. Wu R., and Lefvert A.K. Autoantibodies against oxidized low density lipoprotein (OxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin. Exp. Immunol. 102 (1995) 174-180
24. Bar-Or D., Lau E., and Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J. Emerg. Med. 19 (2000) 311-315
25. Packard R.R.S., and Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 54 (2008) 24-38
26. Reifenberg K., Lehr H.A., Baskal D., et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer?. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1641-1646
27. Postadzhiyan A.S., Tzontcheva A.V., Kehayov I., and Finkov B. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes. Clin. Biochem. 41 (2008) 126-133
28. Stokes K.Y., Gurwara S., and Granger D.N. T-cell-derived interferon-gamma contributes to arteriolar dysfunction during acute hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1998-2004
29. Rodriguez-Porcel M., Lerman A., Best P.J.M., Krier J.D., Napoli C., and Lerman L.O. Hypercholesterolemia impairs myocardial perfusion and permeability: role of oxidative stress and endogenous scavenging activity. J. Am. Coll. Cardiol. 37 (2001) 608-615
30. Madamanchi N.R., Vendrov A., and Runge M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 29-38
31. Armstrong E.J., Morrow D.A., and Sabatine M.S. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 113 (2006) 72-75
32. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
33. Kasap S., Gönenç A., Şener D.E., and Hisar I. Serum cardiac markers in patients with acute myocardial infarction: oxidative stress, C-reactive protein and N-terminal probrain natriuretic peptide. J. Clin. Biochem. Nutr. 41 (2007) 50-57
34. Abramson J.L., Hooper W.C., Jones D.P., et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 178 (2005) 115-121
35. Dusek J., Stasek J., Tichy M., et al. Prognostic significance of ischemia modified albumin after percutaneous coronary intervention. Clin. Chim. Acta 367 (2006) 77-80
36. Bogavac-Stanojević N., Jelić-Ivanović Z., Spasojević-Kalimanovska V., et al. Lipid and inflammatory markers for the prediction of coronary artery disease: a multi-marker approach. Clin. Biochem. 40 (2007) 1000-1006
37. Stokes K.Y., Clanton E.C., Bowles K.S., et al. The role of T-lymphocytes in hypercholesterolemia-induced leukocyte-endothelial interactions. Microcirculation 9 (2002) 407-417
38. Shaw P.X., Horkko S., Tsimikas S., et al. Human derived anti oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1333-1339
39. Tinahones F.J., Gómez-Zumaquero J.M., Garrido-Sánchez L., et al. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J. Lipid. Res. 3 (2005) 452-457
40. Pengo V., Bison E., Ruffatti A., and Iliceto S. Antibodies to oxidized LDL/β2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb. Res. 122 (2008) 556-559
41. Wadham C., Albanese N., Roberts J., et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109 (2004) 2116-2122
42. Mineo C., Deguchi H., Griffin J.H., and Shaul P. Endothelial and antithrombotic actions of HDL. Circ. Res. 98 (2006) 1352-1364
43. Assmann G., and Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 109 (2004) III8-III14
44. Deakin S., Moren X., and James R.W. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1146-1152
45. Jurek A., Turyna B., Kubit P., and Klein A. The ability of HDL to inhibit VCAM-1 expression and oxidized LDL uptake is impaired in renal patients. Clin. Biochem. 41 (2008) 1015-1018